Home / MOTS : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does MOTS make money? Does MOTS have pricing power? What's the Earnings Whisper? Will MOTS profit more as the business scales? What is MOTS's management track record? Is MOTS's current price justified?

Motus GI Holdings, Inc.

$0 +$0.00 (+100.00%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

Day Range

$0$0

Year Range

$0$0.1

Market Cap

1.28K

AVG Volume

1.82K

Trailing/Forward PE

-0/-

PEG ratio

Dividend Yield

Next Earnings Date

2026-11-17

Primary Exchange

Other OTC

Revenue (USD)

MOTS Revenue (USD) by quarter
Period	Revenue (USD)
24 Q1	64K
23 Q4	64K
23 Q3	86K
23 Q2	113K
23 Q1	56K
22 Q4	109K
22 Q3	278K
22 Q2	185K
22 Q1	20K
21 Q4	99K

Net Income (USD)

MOTS Net Income (USD) by quarter
Period	Net Income (USD)
24 Q1	-2.11M
23 Q4	-2.81M
23 Q3	-2.68M
23 Q2	-3M
23 Q1	-4.39M
22 Q4	-3.92M
22 Q3	-5.22M
22 Q2	-5.69M
22 Q1	-5.1M
21 Q4	-4.82M

Operating Income (USD)

MOTS Operating Income (USD) by quarter
Period	Operating Income (USD)
24 Q1	-2.03M
23 Q4	-2.47M
23 Q3	-2.39M
23 Q2	-2.68M
23 Q1	-4.36M
22 Q4	-4.03M
22 Q3	-4.71M
22 Q2	-4.59M
22 Q1	-4.53M
21 Q4	-4.55M

EBITDA (USD)

MOTS EBITDA (USD) by quarter
Period	EBITDA (USD)
24 Q1	-1.88M
23 Q4	-2.59M
23 Q3	-2.29M
23 Q2	-2.64M
23 Q1	-3.96M
22 Q4	-3.23M
22 Q3	-4.45M
22 Q2	-4.56M
22 Q1	-4.28M
21 Q4	-4.32M

Cash Flows (USD)

MOTS Cash Flows (USD) by quarter
Period	Cash Flows (USD)
24 Q1	-2.02M
23 Q4	-2.06M
23 Q3	-1.98M
23 Q2	-2.62M
23 Q1	-4.84M
22 Q4	-4.05M
22 Q3	-3.78M
22 Q2	-4.61M
22 Q1	-5.25M
21 Q4	-3.96M

EPS (USD)

MOTS EPS (USD) by quarter
Period	EPS (USD)
24 Q1	-0.88
23 Q4	-1.81
23 Q3	-4.28
23 Q2	-5.95
23 Q1	-13.81
22 Q4	-12.65
22 Q3	-26.67
22 Q2	-30.92
22 Q1	-29.52
21 Q4	-29.92

Expenses (USD)

MOTS Expenses (USD) by quarter
Period	Expenses (USD)
24 Q1	2.08M
23 Q4	2.25M
23 Q3	2.45M
23 Q2	2.78M
23 Q1	4.28M
22 Q4	3.67M
22 Q3	5.07M
22 Q2	4.76M
22 Q1	4.37M
21 Q4	4.4M

Cash & Debt (USD)

MOTS Cash & Debt (USD) by quarter
Period	Cash & Debt (USD)
24 Q1	4.94M
23 Q4	4.96M
23 Q3	5.72M
23 Q2	8.52M
23 Q1	8.65M
22 Q4	14.04M
22 Q3	13.29M
22 Q2	15.76M
22 Q1	20.34M
21 Q4	22.56M

Debt ratios

MOTS Debt ratios by quarter
Period	Debt ratios
24 Q1	0.27
23 Q4	0.22
23 Q3	-0.31
23 Q2	-0.11
23 Q1	-0.13
22 Q4	0.16
22 Q3	0.07
22 Q2	0.2
22 Q1	0.47
21 Q4	0.6

Margins

MOTS Margins by quarter
Period	Margins
24 Q1	81.25%
23 Q4	-471.88%
23 Q3	44.19%
23 Q2	46.02%
23 Q1	-210.71%
22 Q4	-332.11%
22 Q3	70.14%
22 Q2	63.24%
22 Q1	-770%
21 Q4	-206.06%

Return on Capital

MOTS Return on Capital by quarter
Period	Return on Capital
24 Q1	-68.89%
23 Q4	-104.39%
23 Q3	108.11%
23 Q2	311.21%
23 Q1	404.24%
22 Q4	-131.64%
22 Q3	-685.43%
22 Q2	-143.18%
22 Q1	-59.21%
21 Q4	-49.89%

Shares Outstanding

MOTS Shares Outstanding by quarter
Period	Shares Outstanding
24 Q1	8.61M
23 Q4	1.55M
23 Q3	626.44K
23 Q2	503.73K
23 Q1	317.55K
22 Q4	309.79K
22 Q3	195.84K
22 Q2	183.9K
22 Q1	172.65K
21 Q4	161.02K

Book Value Per Share (USD)

MOTS Book Value Per Share (USD) by quarter
Period	Book Value Per Share (USD)
24 Q1	0.36
23 Q4	1.73
23 Q3	-3.96
23 Q2	-1.91
23 Q1	-3.42
22 Q4	9.61
22 Q3	3.89
22 Q2	21.6
22 Q1	49.85
21 Q4	59.97

Total Assets (USD)

MOTS Total Assets (USD) by quarter
Period	Total Assets (USD)
24 Q1	7.07M
23 Q4	7.22M
23 Q3	8.49M
23 Q2	11.74M
23 Q1	12.23M
22 Q4	17.65M
22 Q3	17.37M
22 Q2	20.08M
22 Q1	24.43M
21 Q4	26.09M

Employee Count

MOTS Employee Count by quarter
Period	Employee Count
2023	15
2022	43
2021	30
2020	24
2019	49
2018	44
2017	39

Free Cash Flow Yield

MOTS Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-503877.55%
Sep 26	-503877.54%
Aug 26	-1007755.1%
Aug 26	-1007755.1%
Aug 26	-1007755.1%
Aug 26	-1007755.1%
Jul 26	-1007755.07%
Jul 26	-1007755.1%
Jul 26	-1007755.1%
Jul 26	-1007755.1%
Jul 26	-1007755.07%
Jun 26	-1007755.1%
Jun 26	-1007755.1%
Jun 26	-1007755.07%
Jun 26	-1007755.1%
May 26	-1007755.1%
May 26	-1007755.1%
May 26	-1007755.1%
May 26	-1007755.1%
May 26	-1007755.1%
Apr 26	-1007755.1%
Apr 26	-1007755.1%
Apr 26	-1007755.1%
Apr 26	-1007755.1%
Mar 26	-1007755.1%
Mar 26	-1007755.1%
Mar 26	-1007755.1%
Mar 26	-1007755.1%
Feb 26	-1007755.07%
Feb 26	-503877.55%
Feb 26	-503877.55%
Feb 26	-1007755.1%
Jan 26	-1007755.1%
Jan 26	-100775507%
Jan 26	-1007755.1%
Jan 26	-1007755.1%
Jan 26	-1007755.1%
Dec 25	-1007755.07%
Dec 25	-1007755.1%
Dec 25	-1007755.1%
Dec 25	-1007755.1%
Nov 25	-1007755.07%
Nov 25	-503877.54%
Nov 25	-503877.54%
Nov 25	-1007755.1%
Oct 25	-1007755.1%
Oct 25	-503877.54%
Oct 25	-1007755.1%
Oct 25	-1007755.1%
Oct 25	-10077550.7%
Sep 25	-10077550.7%
Sep 25	-1007755.07%
Sep 25	-1007755.1%
Sep 25	-1007755.1%
Aug 25	-100775507%
Aug 25	-1007755.07%
Aug 25	-1007755.1%
Aug 25	-1007755.07%
Aug 25	-100775507%
Jul 25	-1007755.1%
Jul 25	-1007755.07%
Jul 25	-335918.34%
Jul 25	-335918.34%
Jun 25	-335918.34%
Jun 25	-335918.34%
Jun 25	-335918.34%
Jun 25	-335918.34%
May 25	-335918.34%
May 25	-335918.34%
May 25	-1007755.1%
May 25	-1007755.1%
May 25	-1007755.1%
Apr 25	-1007755.1%
Apr 25	-1007755.1%
Apr 25	-1007755.1%
Apr 25	-1007755.1%
Mar 25	-1007755.1%
Mar 25	-1007755.1%
Mar 25	-1007755.1%
Mar 25	-1007755.1%
Feb 25	-1007755.1%
Feb 25	-1007755.1%
Feb 25	-503877.55%
Feb 25	-503877.55%
Jan 25	-1007755.07%
Jan 25	-1007755.07%
Jan 25	-1007755.07%
Jan 25	-1007755.1%
Jan 25	-1007755.07%
Dec 24	-1007755.07%
Dec 24	-1007755.07%
Dec 24	-503877.54%
Dec 24	-251938.77%
Nov 24	-1007755.07%
Nov 24	-335918.36%
Nov 24	-251938.77%
Nov 24	-251938.77%
Nov 24	-100775.51%
Oct 24	-67183.67%
Oct 24	-80620.41%

Price to Sales

MOTS Price to Sales by quarter
Period	Price to Sales
Sep 26	0.01
Sep 26	0.01
Aug 26	0
Aug 26	0
Aug 26	0
Aug 26	0
Jul 26	0
Jul 26	0
Jul 26	0
Jul 26	0
Jul 26	0
Jun 26	0
Jun 26	0
Jun 26	0
Jun 26	0
May 26	0
May 26	0
May 26	0
May 26	0
May 26	0
Apr 26	0
Apr 26	0
Apr 26	0
Apr 26	0
Mar 26	0
Mar 26	0
Mar 26	0
Mar 26	0
Feb 26	0
Feb 26	0.01
Feb 26	0.01
Feb 26	0
Jan 26	0
Jan 26	0
Jan 26	0
Jan 26	0
Jan 26	0
Dec 25	0
Dec 25	0
Dec 25	0
Dec 25	0
Nov 25	0
Nov 25	0.01
Nov 25	0.01
Nov 25	0
Oct 25	0
Oct 25	0.01
Oct 25	0
Oct 25	0
Oct 25	0
Sep 25	0
Sep 25	0
Sep 25	0
Sep 25	0
Aug 25	0
Aug 25	0
Aug 25	0
Aug 25	0
Aug 25	0
Jul 25	0
Jul 25	0
Jul 25	0.01
Jul 25	0.01
Jun 25	0.01
Jun 25	0.01
Jun 25	0.01
Jun 25	0.01
May 25	0.01
May 25	0.01
May 25	0
May 25	0
May 25	0
Apr 25	0
Apr 25	0
Apr 25	0
Apr 25	0
Mar 25	0
Mar 25	0
Mar 25	0
Mar 25	0
Feb 25	0
Feb 25	0
Feb 25	0.01
Feb 25	0.01
Jan 25	0
Jan 25	0
Jan 25	0
Jan 25	0
Jan 25	0
Dec 24	0
Dec 24	0
Dec 24	0.01
Dec 24	0.01
Nov 24	0
Nov 24	0.01
Nov 24	0.01
Nov 24	0.01
Nov 24	0.03
Oct 24	0.04
Oct 24	0.03

Price to Book

MOTS Price to Book by quarter
Period	Price to Book
Sep 26	0
Sep 26	0
Aug 26	0
Aug 26	0
Aug 26	0
Aug 26	0
Jul 26	0
Jul 26	0
Jul 26	0
Jul 26	0
Jul 26	0
Jun 26	0
Jun 26	0
Jun 26	0
Jun 26	0
May 26	0
May 26	0
May 26	0
May 26	0
May 26	0
Apr 26	0
Apr 26	0
Apr 26	0
Apr 26	0
Mar 26	0
Mar 26	0
Mar 26	0
Mar 26	0
Feb 26	0
Feb 26	0
Feb 26	0
Feb 26	0
Jan 26	0
Jan 26	0
Jan 26	0
Jan 26	0
Jan 26	0
Dec 25	0
Dec 25	0
Dec 25	0
Dec 25	0
Nov 25	0
Nov 25	0
Nov 25	0
Nov 25	0
Oct 25	0
Oct 25	0
Oct 25	0
Oct 25	0
Oct 25	0
Sep 25	0
Sep 25	0
Sep 25	0
Sep 25	0
Aug 25	0
Aug 25	0
Aug 25	0
Aug 25	0
Aug 25	0
Jul 25	0
Jul 25	0
Jul 25	0
Jul 25	0
Jun 25	0
Jun 25	0
Jun 25	0
Jun 25	0
May 25	0
May 25	0
May 25	0
May 25	0
May 25	0
Apr 25	0
Apr 25	0
Apr 25	0
Apr 25	0
Mar 25	0
Mar 25	0
Mar 25	0
Mar 25	0
Feb 25	0
Feb 25	0
Feb 25	0
Feb 25	0
Jan 25	0
Jan 25	0
Jan 25	0
Jan 25	0
Jan 25	0
Dec 24	0
Dec 24	0
Dec 24	0
Dec 24	0
Nov 24	0
Nov 24	0
Nov 24	0
Nov 24	0
Nov 24	0
Oct 24	0
Oct 24	0

No video analysis for this stock yet. Request one from our team.

News: MOTS

accessnewswire.com · 28 Jul 2026

Vanta Commends U.S. FDA Advisory Committee Vote Recommending Inclusion of Six Peptide Substances on FDA's 503A Bulks List, Including BPC-157, TB-500 and MOTS-c

News Release Highlights: U.S. FDA Pharmacy Compounding Advisory Committee recommends the inclusion of six peptide substances, including BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, on the FDA's 503A Bulks List, representing a significant step in the FDA's ongoing regulatory review process for these peptide substances. Vanta has established a strategic operating framework supporting its contemplated U.S. peptide platform, including telehealth-enabled commercialization, FDA-registered compounding pharmacy coordination, peptide manufacturing and fulfillment capabilities, and compliant payment processing infrastructure.

AI Analysis

Motus GI Holdings, Inc.

Video analysis: MOTS

News: MOTS

Vanta Commends U.S. FDA Advisory Committee Vote Recommending Inclusion of Six Peptide Substances on FDA's 503A Bulks List, Including BPC-157, TB-500 and MOTS-c

Similar companies